CEL-SCI Corporation

Healthcare · Biotechnology · United States

Last price 1.45 USD (Oct 30, 2026, 9:39 AM EDT) · Market cap 25.50M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company’s lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections,...